MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
2.290
+0.080
+3.62%
Opening 13:50 03/25 EDT
OPEN
2.260
PREV CLOSE
2.210
HIGH
2.370
LOW
2.260
VOLUME
2.36M
TURNOVER
--
52 WEEK HIGH
2.800
52 WEEK LOW
0.8621
MARKET CAP
558.25M
P/E (TTM)
-2.6468
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 2d ago
Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday
Benzinga · 2d ago
Weekly Report: what happened at ALLO last week (0316-0320)?
Weekly Report · 2d ago
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value
Seeking Alpha · 03/17 13:38
Weekly Report: what happened at ALLO last week (0309-0313)?
Weekly Report · 03/16 09:46
Allogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks
TipRanks · 03/14 06:01
Allogene Therapeutics Banks on 2026 Trial Catalysts
TipRanks · 03/14 00:03
Allogene Therapeutics Price Target Maintained With a $14.00/Share by Canaccord Genuity
Dow Jones · 03/13 18:20
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.